As part of the 2025 North American Neuroendocrine Tumor Society Multidisciplinary NET Medical Symposium in Austin, Texas, CancerNetwork sat down with Joseph Dillon, MBBCh, BAO, to discuss his presentation focused on the current uses and risks associated with glucagon-like peptide-1 (GLP-1) receptor agonists for patients who are undergoing treatment for neuroendocrine tumors (NETs)
Retatrutide vs Tirzepatide: Triple Agonist vs Dual Agonist Comparison for Metabolic Research Retatrutide, a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, demonstrates unprecedented weight loss efficacy in clinical trialsup to 24.2% body weight reduction at 48 weeks
Thomson (18561940) and Ernest Rutherford (18711937), who investigated the relationship between electrical conductivity and gaseous media in 1896 (Thomson and Rutherford, 1896)
Most assume medications are unaffordable or are unaware of their insurance coverage